Kahn Swick & Foti, LLC is notifying investors of Ultragenyx Pharmaceutical Inc. (NasdaqGS: RARE) about a class action securities lawsuit. The lawsuit seeks to recover losses for investors affected by alleged securities fraud between August 3, 2023, and December 26, 2025, following the failure of two Phase 3 studies that caused a significant drop in stock price. Investors have until April 6, 2026, to request to be appointed as lead plaintiff.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026
Kahn Swick & Foti, LLC is notifying investors of Ultragenyx Pharmaceutical Inc. (NasdaqGS: RARE) about a class action securities lawsuit. The lawsuit seeks to recover losses for investors affected by alleged securities fraud between August 3, 2023, and December 26, 2025, following the failure of two Phase 3 studies that caused a significant drop in stock price. Investors have until April 6, 2026, to request to be appointed as lead plaintiff.